ENTBF News and Press, Entheon Biomedical Corp Com

2024-03-27 17:08:02 ET Addiction is an issue that affects a significant number of people worldwide. While conventional treatments have existed for decades, they offer a very low rate of efficacy, often as low as 5%. For Timothy Ko , CEO of Entheon Biomedical , the problem ...

2024-03-27 17:08:02 ET Leading-edge addiction recovery solution Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses the therapeutic potential of patient-centric psychedelic medicine to remedy the underlying causes of Substance Use Disorde...

2024-01-12 13:06:40 ET More on Entheon Biomedical Corp. Financial information for Entheon Biomedical Corp. For further details see: RBC downgrades 89Bio to sector perform, cites fewer near-term catalysts

2024-01-12 11:01:35 ET More on Entheon Biomedical Corp., Nevro, etc. Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript) Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade) Regeneron Pharmaceuticals In...

MIAMI, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”) , a Healthcare Analytics provider with interests in the psychedelic and mental health sectors, today issued a letter to shareholders from its Chief Executive Officer, Ben Kaplan. Dear Fel...

Palm Beach, FL – July 27, 2022 – For years, ketamine was known for its use as an anesthetic or as a recreational drug. Its ability to provide quick and safe sedation saved many lives during the Vietnam war and is still the preferred anesthetic in battlefield situations...

Cybin (NYSE American: CYBN) (NEO: CYBN) , a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced that, through its wholly-owned subsidiary Cybin IRL Limited, it has completed the acquisition of a phase 1 N,N-dimethyltryptamine (&...

Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine (“DMT”) study from Canadian biotech Entheon Biomedical Corp. (OTCQB:ENTBF)....

AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinic Genetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted th...

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalize...